Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain
An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Naïve Patients With Chronic Low Back Pain
Sponsor: Endo Pharmaceuticals
Listed as NCT00225797, this PHASE3 trial focuses on Chronic Pain and remains completed. Sponsored by Endo Pharmaceuticals, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Feb 2024 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Nov 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Endo Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Altoona, United States , Atlanta, United States , Bridgeport, United States , Burr Ridge, United States , Collegeville, United States , Colorado Springs, United States , Cranston, United States , Daytona Beach, United States , DeLand, United States , Feasterville, United States and 20 more locations